Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | CUPISCO & GEFCAPI04: molecularly-guided therapy in cancer of unknown primary

Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK, gives us an update on the CUPISCO trial (NCT03498521). This Phase II study compares the efficacy and safety of targeted therapy or immunotherapy guided by genomic profiling versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP). Dr Shiu also discusses the implications of the GEFCAPI04 trial (NCT01540058). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.